Accentia Biopharmaceuticals, Inc. to Present at the Jefferies Life Sciences Conference.TAMPA BAY Tampa Bay, inlet of the Gulf of Mexico, 25 mi (40 km) long and 7 to 12 mi (11.3–19 km) wide, W Fla., separated from the Gulf by numerous small islands; it receives the Hillsborough River. St. , Fla. -- First graph, first sentence of release dated June 23, 2006 should read xxx will present at the Jefferies Life Sciences Conference in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. Wednesday, June 28th (sted: Tuesday, June 28th). The corrected release reads: ACCENTIA BIOPHARMACEUTICALS, INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . TO PRESENT AT THE JEFFERIES LIFE SCIENCES CONFERENCE Company to Discuss SinuNase(TM), a Novel Therapeutic for the Treatment of Chronic Sinusitis chronic sinusitis Chronic sinus infection ENT Inflammation of the sinuses that empty into the nasal cavity Etiology Allergic rhinitis, nasal obstruction, deviated nasal septum, tooth abscesses, URIs Currently Entering Phase 3 Clinical Trials phase 3 clinical trial Phase 3 study. See Phase study. Accentia Biopharmaceuticals, Inc. (Nasdaq: ABPI ABPI Association of the British Pharmaceutical Industry ABPI Associação Brasileira da Propriedade Intelectual (Brazilian Intellectual Property Association; Brazil) ABPI Ankle Brachial Pressure Index ; Accentia), a biopharmaceutical company focused on the development and commercialization of late-stage clinical products in the therapeutic areas of respiratory disease Noun 1. respiratory disease - a disease affecting the respiratory system respiratory disorder, respiratory illness adult respiratory distress syndrome, ARDS, wet lung, white lung - acute lung injury characterized by coughing and rales; inflammation of the and oncology, will present at the Jefferies Life Sciences Conference in New York City Wednesday, June 28th, at 1:15 p.m. E.T. Frank O'Donnell Francis Joseph "Frank" O'Donnell (August 31 1911 — September 4 1952) was a Scottish professional footballer. He was the older brother of fellow footballer Hugh O'Donnell, who also played for Blackpool and Preston North End. , MD, Accentia Biopharmaceuticals Chairman and Chief Executive Officer, will address attendees. Accentia is one of more than 100 life science companies scheduled to present at the conference to be held Tuesday, June 27 through Wednesday, June 28, 2006. Dr. O'Donnell's presentation will focus on updating the investment community on the Company's SinuNase product, currently entering Phase 3 clinical trials. SinuNase is in development to treat chronic sinusitis (CS), a disease that affects roughly 31 million Americans. There is currently no approved pharmaceutical treatment available in the area of chronic sinusitis. SinuNase was granted fast-track status by the Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) in April of this year. Members of the financial and investment community, the media and other interested parties can access a live audio webcast of Accentia's presentation by accessing the following Jefferies conference link: http://www.wsw.com/webcast/jeff11/abpi. The presentation will be available and archived for 90 days. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of late-stage clinical products in the therapeutic areas of respiratory disease and oncology. Two of these products are SinuNase(TM) and BiovaxID. The Company's SinuNase(TM) product, in development to treat chronic sinusitis (rhinosinusitis), is a novel application and formulation of a known anti-fungal licensed from the Mayo Foundation for Medical Education and Research. BiovaxID is a patient-specific anti-cancer vaccine focusing on the treatment of follicular fol·lic·u·lar adj. 1. Relating to, having, or resembling a follicle or follicles. 2. Affecting or growing out of a follicle or follicles. non-Hodgkin's lymphoma non-Hodg·kin's lymphoma n. Any of various malignant lymphomas characterized by the absence of Reed-Sternberg cells. Non-Hodgkin's lymphoma . BiovaxID, which is being developed by Accentia's subsidiary Biovest International, Inc., is currently in a Phase 3 clinical trial. In addition, Accentia's growing specialty pharmaceutical business, TEAMM Pharmaceuticals, has a portfolio of currently marketed products plus a pipeline of additional products under development by third parties. For further information, please visit our web site: www.accentia.net. Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about SinuNase and any other statements relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc products, product candidates, product development programs the FDA or clinical trial process including the commencement, process or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Accentia to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward looking statements are qualified in their entirety by this cautionary statement, and neither Accentia undertakes any obligation to revise or update this news release to reflect events or circumstances after the date hereof. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion